The pharmaceutical industry plays a critical role in ensuring patients have access to necessary medications. However, when companies violate antitrust laws to restrict market competition, it can lead to inflated prices and limited consumer choices. Recently, AstraZeneca and Handa Pharmaceuticals agreed to a combined $5.475 million settlement, resolving allegations that they unlawfully prevented generic alternatives to Seroquel XR from reaching the market. The Seroquel XR class action settlement presents an opportunity for eligible entities to reclaim funds potentially overpaid due to these alleged antitrust activities.

If you’ve followed past victories like the CVS eye drops class action settlement, you already know Sparrow is committed to helping consumers recover what’s rightfully theirs. In this article, we’ll walk you through eligibility details, reimbursement options, and how Sparrow makes the claim process hassle-free.

Table of Contents

• Detailed Background of the Case
• Who’s Eligible for the Seroquel XR Class Action Settlement?
• How Much Can You Receive from the Settlement?
• How to File Your Claim
• Important Deadlines
• Official Case Information
• Conclusion

Detailed Background of the Case

The lawsuit, titled In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation, alleged that AstraZeneca and Handa Pharmaceuticals engaged in unlawful practices to delay the entry of generic versions of Seroquel XR, known as quetiapine fumarate ER, into the marketplace. By doing so, the companies purportedly created an unfair monopoly, significantly inflating the cost of medication and limiting affordable alternatives for consumers and third-party payers.

The allegations focused on antitrust violations under state laws, asserting that AstraZeneca and Handa Pharmaceuticals deliberately took actions designed to maintain market dominance for branded Seroquel XR, a medication commonly prescribed to treat schizophrenia, bipolar disorder, and depression. This practice allegedly led third-party payers to overpay for medications due to lack of competitive pricing.

Both AstraZeneca and Handa Pharmaceuticals have denied wrongdoing but chose to settle the claims to avoid prolonged litigation. This resolution highlights ongoing concerns regarding pharmaceutical pricing and market competition, underscoring the importance of holding corporations accountable to ensure fair access to essential medications.

Who’s Eligible for the Seroquel XR Class Action Settlement?

You might qualify for compensation from this settlement if you:

• Purchased, paid for, or provided reimbursement for Seroquel XR or generic quetiapine fumarate ER (in strengths of 50 mg, 150 mg, 200 mg, and/or 300 mg tablets).
• Made purchases in one of the eligible states between September 5, 2015, and December 9, 2024.

Eligible states include:

• Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Vermont, West Virginia, Wisconsin.

How Much Can You Receive from the Settlement?

The settlement provides monetary compensation based on the amount you paid or reimbursed for Seroquel XR or its generic equivalents during the eligibility period. Specific payment amounts will vary and depend on the total claims submitted and the documented expenses.

How to File Your Claim

To claim your portion of the Seroquel XR settlement:

1. Visit the official settlement website at SeroquelXRAntitrustSettlement.com.
2. Gather documentation verifying your purchases or reimbursements for Seroquel XR or generic quetiapine fumarate ER.
3. Submit your completed claim form and necessary documentation through the online portal or mail your claim to the provided address before the deadline.

Let Sparrow simplify your process—visit our Sparrow Claim Assistance page to get expert help with filing your claim efficiently and accurately.

Important Deadlines

Mark your calendars with these essential dates:

• Claim Form Deadline: June 9, 2025
• Final Approval Hearing: April 23, 2025
• Exclusion and Objection Deadline: February 24, 2025 (Passed)

Official Case Information

• Case Name: In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation, Case No. 1:20-cv-01076-CFC, U.S. District Court for the District of Delaware
• Settlement Website: SeroquelXRAntitrustSettlement.com
• Claims Administrator:
  • Claims Administrator
  • P.O. Box 5017
  • Portland, OR 97208-5017
  • Email: info@SeroquelXRAntitrustSettlement.com
  • Phone: 888-884-8072

Conclusion

The Seroquel XR class action settlement represents a critical step towards rectifying alleged antitrust practices in the pharmaceutical market, ensuring fairer pricing and increased availability of essential generic medications. If you or your organization overpaid for Seroquel XR due to these practices, this is your opportunity to reclaim your funds. Sparrow is here to streamline the process and ensure you receive the compensation you’re entitled to. Start your claim today with Sparrow and take advantage of this significant settlement.

Stay connected with Sparrow for more updates and settlements.